This inventor holds 3 USPTO granted patents. Top assignees: Centre Hospitalier Universitaire Vaudois, Ludwig Institute for Cancer Research Limited, Université De Lausanne. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 27 
2 out of 530 
1 out of 26 Years Active: 2025-2026
Title: Steven M Dunn: Innovator in Cancer Treatment
Introduction
Steven M Dunn is a notable inventor based in Epalinges, Switzerland. He has made significant contributions to the field of cancer research through his innovative work on antibodies.
Latest Patents
Dunn holds a patent for "Anti-TEM1 antibodies and antigen-binding portions thereof." This patent provides antibodies and antigen-binding portions that specifically bind to tumor endothelial marker 1 (TEM1). The methods disclosed in this patent include treating cancer, reducing tumor growth, minimizing tumor metastasis, and alleviating tumor-associated fibrosis in subjects in need.
Career Highlights
Throughout his career, Steven M Dunn has worked with prestigious organizations such as the Ludwig Institute for Cancer Research Limited and the Centre Hospitalier Universitaire Vaudois. His work has been instrumental in advancing cancer treatment methodologies.
Collaborations
Dunn has collaborated with esteemed colleagues, including Julie K Fierle and George Coukos, further enhancing the impact of his research in the medical community.
Conclusion
Steven M Dunn's innovative contributions to cancer treatment through his patent on Anti-TEM1 antibodies exemplify his commitment to improving patient outcomes. His work continues to influence the field of cancer research significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile